EQT Partners är rådgivare till samtliga EQT-fonder. EQT har cirka 650 anställda varav cirka 300 är investeringsspecialister med omfattande industriell och finansiell kompetens. [ 3 ] EQT Partners har kontor i Köpenhamn , Frankfurt , Helsingfors , Hongkong , Oslo , London , Madrid , Milano , München , New York , Shanghai , Singapore , Stockholm och Zürich .

Private Equity EQT Offers To Acquire Swedish Pharma Recipharm For $2.1B

Den 14 december 2020 offentliggjorde EQT IX1 ("EQT IX"), genom offentliggör slutligt utfall i erbjudandet till aktieägarna i Recipharm AB i Hembla AB · Offer to the shareholders in Hembla AB. EQT. Invitation to acquire shares in EQT AB (publ) · Inbjudan till förvärv av aktier i EQT AB (publ) E-post: recipharm@lucid-is.com. Informationen i detta pressmeddelande lämnades för offentliggörande av Roar BidCo (kontaktdetaljer till EQT Linden Advisors har minskat sin blankning i läkemedelsbolaget Recipharm från 1,06 Totalt är nu 1,54 procent blankat i Recipharm, som EQT lagt ett bud på. Relais Group Oyj: Strategically important acquisition to boost growth and online Affär EQT, genom Roar Bidco, kontrollerar nu cirka 95,1 procent av aktierna och cirka 98,3 procent av rösterna i kontraktstillverkaren EQT IX har, genom Roar BidCo, offentliggjort ett offentligt uppköpserbjudande om 220 kronor kontant per aktie till aktieägarna i Recipharm, Riskkapitalbolaget EQT höjer budet på Recipharm från 220 till 232 kronor per aktie. Finwire. Publicerad 2021-01-28. Konvertibelinnehavarna erbjuds 1 504 295 2021-03-01 15:30:00 Tender offer, Roar BidCo offentliggör slutligt utfall i erbjudandet till aktieägarna i Recipharm AB (publ) och Konvertibelinnehavarna.

Recipharm acquired by eqt

moms. Buyout group EQT on Thursday raised its cash offer for contract pharmaceutical maker Recipharm, valuing the Swedish company at 24.9 billion Swedish crowns ($2.97 billion). EQT said Monday it’s offering shareholders 220 kronor in cash per share, 23% more than Friday’s closing price. Recipharm is a 25-year-old company that specializes in outsourcing contract manufacturing services to help pharmaceutical companies develop new drugs. EQT IX, through Roar BidCo AB, announces a public offer of SEK 220 in cash per share to the shareholders of Recipharm AB (publ) and SEK 1,427,010 in cash per Convertible Bond. 14 December 2020.

On December 14, 2020, EQT IX (“EQT”), through Roar BidCo AB (“Roar BidCo”), announced a public tender offer to the shareholders of Recipharm AB (“Recipharm”) to tender all their shares in Recipharm to Roar BidCo for SEK 220 per share and SEK 1,427,010 per convertible bond.

2020-12-14 2021-03-17 The Board of Directors unanimously recommends the shareholders and holders of convertible bonds to accept the offer from Roar BidCo. This statement is made by the board of directors of Recipharm AB (publ) (“Recipharm”) pursuant to Rule II.19 of the Nasdaq Stockholm Takeover Rules … STOCKHOLM--Swedish private-equity firm EQT AB on Monday declared its offer for pharmaceutical development and manufacturing company Recipharm AB unconditional. EQT IX, through Roar BidCo AB, made an original bid for Recipharm in December that valued the company at 23.64 billion Swedish kronor ($2.85 billion), but raised the bid to SEK24.93 billion last month.

14 Dec 2020 Stockholm headquartered private equity group EQT AB will buy Swedish pharma company Recipharm AB for $2.1 billion, according to

90. 1. AK&M 15 December 2020 12:32. Buyout group EQT announced December 15 a cash offer for Recipharm valuing the company at 23.6 billion Swedish crowns ($2.80 billion), as it was informed by EQT. Som en mycket aktiv investerare inom den globala hälsovårdssektorn, är EQT väl positionerade att hjälpa Recipharm att framtidssäkra verksamheten och accelerera sin tillväxt. Vi är övertygade om att vi kan tillföra betydande värde, både i form av expertis och kapital, säger Erika Henriksson, Partner på EQT Partners och investeringsrådgivare åt EQT IX, i en skriftlig kommentar.

#Press Release.
Lansforsakringar utbetalning

EQT har cirka 650 anställda varav cirka 300 är investeringsspecialister med omfattande industriell och finansiell kompetens.

Den 14 december 2020 offentliggjorde EQT IX 1 ("EQT IX"), genom Roar BidCo AB 2 ("Roar BidCo"), ett offentligt uppköpserbjudande till aktieägarna och innehavarna av seniora, icke säkerställda konvertibler ("Konvertiblerna") ("Konvertibelinnehavarna") i Recipharm AB (publ) ("Recipharm" eller "Bolaget") att överlåta samtliga sina aktier 3 och Konvertibler till Roar BidCo ("Erbjudandet").
Nervceller kommunikation

konsten heter snörlek vad heter mönstret
invoice receipt in sap
garantitid enligt abt 06
anders hejlsberg salary
religion och vetenskap
text tecken trema

During the extended acceptance period, Roar BidCo has also acquired 713,897 shares in Recipharm in the market, corresponding to approximately 0.7 per cent ofthe share capital and approximately 0.2

EQT IX, through Roar BidCo AB, announces a public offer of SEK 220 in cash per share to the shareholders of Recipharm AB (publ) and SEK 1,427,010 in cash per Convertible Bond. 14 December 2020.

Så kallad förkortning
körkort bild krav

Den 14 december 2020 lämnade EQT IX genom Roar BidCo AB (”Budgivaren”) ett Lars Backsell, styrelseordförande i Recipharm, och Thomas Eldered, databaser, såsom Capital IQ, Refinitiv Eikon och Mergermarket, och

(Bloomberg) -- Private equity firm EQT AB agreed to buy Swedish pharmaceuticals company Recipharm AB for $2.1 billion, marking the latest in a wave of drug industry acquisitions. EQT said Monday it’s offering shareholders 220 kronor in cash per share, 23% more than Friday’s closing price. Stockholm headquartered private equity group EQT AB will buy Swedish pharma company Recipharm AB for $2.1 billion, according to company's press release. The transaction will be routed through Roar EQT IX has offered to acquire Recipharm for $ $2.1bn. (Credit: Gerd Altmann from Pixabay) Via newly established Swedish limited liability company Roar BidCo AB, EQT IX has announced a public offer of SEK220 ($26.1) in cash per share to the shareholders of Recipharm. On December 14, 2020, EQT IX (“EQT”), through Roar BidCo AB (“Roar BidCo”), announced a public tender offer to the shareholders of Recipharm AB (“Recipharm”) to tender all their shares in Recipharm to Roar BidCo for SEK 220 per share and SEK 1,427,010 per convertible bond. Latham & Watkins advised on the financing for EQT’s agreement to buy Swedish pharmaceuticals company Recipharm for US$2.1 billion (SEK17.9 billion).